National Heart, Lung, and Blood Institute; Notice of Meeting, 54816-54817 [2016-19545]
Download as PDF
54816
Federal Register / Vol. 81, No. 159 / Wednesday, August 17, 2016 / Notices
Place: National Institutes of Health,
Building 31, C-Wing, 6th Floor, Room 9 and
10, 31 Center Drive, Bethesda, MD 20892.
Contact Person: Sheila A. Prindiville, MD,
MPH, Director, Coordinating Center for
Clinical Trials, National Institutes of Health,
National Cancer Institute, 9609 Medical
Center Drive, Room 6W136, Rockville, MD
20850, 240–276–6173, prindivs@
mail.nih.gov.
Any interested person may file
written comments with the committee
by forwarding the statement to the
Contact Person listed on this notice. The
statement should include the name,
address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
instituted stringent procedures for
entrance onto the NIH campus. All
visitor vehicles, including taxicabs,
hotel, and airport shuttles will be
inspected before being allowed on
campus. Visitors will be asked to show
one form of identification (for example,
a government-issued photo ID, driver’s
license, or passport) and to state the
purpose of their visit.
Information is also available on the
Institute’s/Center’s home page: https://
deainfo.nci.nih.gov/advisory/ctac/
ctac.htm, where an agenda and any
additional information for the meeting
will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: August 11, 2016.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–19543 Filed 8–16–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
mstockstill on DSK3G9T082PROD with NOTICES
National Institute of Environmental
Health Sciences; Notice of Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the
National Advisory Environmental
Health Sciences Council.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
VerDate Sep<11>2014
16:39 Aug 16, 2016
Jkt 238001
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Advisory
Environmental Health Sciences Council.
Date: September 13, 2016.
Closed: September 13, 2016, 8:30 a.m. to
9:30 a.m.
Agenda: To review and evaluate grant
applications.
Place: Nat. Inst. of Environmental Health
Sciences, Building 101, Rodbell Auditorium,
111 T. W. Alexander Drive, Research
Triangle Park, NC 27709.
Open: September 13, 2016, 9:30 a.m. to
4:15 p.m.
Agenda: Discussion of program policies
and issues.
Place: Nat. Inst. of Environmental Health
Sciences, Building 101, Rodbell Auditorium,
111 T. W. Alexander Drive, Research
Triangle Park, NC 27709.
Contact Person: Gwen W. Collman, Ph.D.,
Director, Division of Extramural Research &
Training, National Institutes of Health, Nat.
Inst. of Environmental Health Sciences, 615
Davis Dr., KEY615/3112, Research Triangle
Park, NC 27709, (919) 541–4980,
collman@niehs.nih.gov.
Any interested person may file
written comments with the committee
by forwarding the statement to the
Contact Person listed on this notice. The
statement should include the name,
address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
Information is also available on the
Institute’s/Center’s home page: https://
www.niehs.nih.gov/about/boards/
naehsc/, where an agenda and any
additional information for the meeting
will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.115, Biometry and Risk
Estimation—Health Risks from
Environmental Exposures; 93.142, NIEHS
Hazardous Waste Worker Health and Safety
Training; 93.143, NIEHS Superfund
Hazardous Substances—Basic Research and
Education; 93.894, Resources and Manpower
Development in the Environmental Health
Sciences; 93.113, Biological Response to
Environmental Health Hazards; 93.114,
Applied Toxicological Research and Testing,
National Institutes of Health, HHS)
PO 00000
Frm 00031
Fmt 4703
Sfmt 4703
Dated: August 10, 2016.
Carolyn Baum,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–19548 Filed 8–16–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood
Institute; Notice of Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the
National Heart, Lung, and Blood
Advisory Council.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
Name of Committee: National Heart, Lung,
and Blood Advisory Council.
Date: September 20, 2016.
Open: 1:00 p.m. to 5:00 p.m.
Agenda: To discuss program policies and
issues.
Place: National Institutes of Health,
Building 35A, Porter Building, Room 640,
35A Convent Drive, Bethesda, MD 20892.
Contact Person: Valerie L. Prenger, Ph.D.,
MPH, Acting Division Director, Division of
Extramural Research Activities, National
Heart, Lung, and Blood Institute, 6701
Rockledge Drive, Room 7214, Bethesda, MD
20892–7924, 301–435–0270,
prengerv@nhlbi.nih.gov.
Any interested person may file
written comments with the committee
by forwarding the statement to the
Contact Person listed on this notice. The
statement should include the name,
address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
instituted stringent procedures for
entrance onto the NIH campus. All
visitor vehicles, including taxicabs,
hotel, and airport shuttles will be
inspected before being allowed on
campus. Visitors will be asked to show
one form of identification (for example,
a government-issued photo ID, driver’s
license, or passport) and to state the
purpose of their visit.
Information is also available on the
Institute’s/Center’s home page:
www.nhlbi.nih.gov/meetings/nhlbac/
index.htm, where an agenda and any
E:\FR\FM\17AUN1.SGM
17AUN1
Federal Register / Vol. 81, No. 159 / Wednesday, August 17, 2016 / Notices
additional information for the meeting
will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
Dated: August 11, 2016.
Michelle Trout,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–19545 Filed 8–16–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Amended
Notice of Meeting
Notice is hereby given of a change in
the meeting of the National Cancer
Advisory Board, September 07, 2016,
09:00 a.m. to September 07, 2016, 5:00
p.m., National Institutes of Health,
Building 31, 31 Center Drive,
Conference Room 10, Bethesda, MD
20892 which was published in the
Federal Register on August 08, 2016, 81
FR 52452.
This meeting notice has been
amended to change the end time of the
open session to 2:45 p.m. The closed
session has also been amended to begin
at 3:00 p.m. and end at 4:15 p.m. The
meeting is partially closed to the public.
Dated: August 11, 2016.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–19544 Filed 8–16–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive Patent
License: Development of T Cell
Receptors (TCRs) Targeting the KRAS
G12D Mutation for the Treatment of
Cancer
mstockstill on DSK3G9T082PROD with NOTICES
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
This is notice, in accordance
with 35 U.S.C. 209 and 37 CFR part 404,
that the National Cancer Institute,
National Institutes of Health,
Department of Health and Human
Services, is contemplating the grant of
SUMMARY:
VerDate Sep<11>2014
16:39 Aug 16, 2016
Jkt 238001
an exclusive patent license to Kite
Pharma, Inc. (‘‘Kite’’) located in Santa
Monica, CA to practice the inventions
embodied in the following patent
applications:
Intellectual Property
United States Provisional Patent
Application No. 62/084,654, filed
November 26, 2014, entitled ‘‘Antimutated KRAS T Cell Receptors’’ [HHS
Reference No. E–028–2015/0–US–01];
and
PCT Application No. PCT/US2015/
062269 filed November 24, 2015
entitled ‘‘Anti-mutated KRAS T Cell
Receptors’’ [HHS Reference No. E–028–
2015/1–PCT–01].
The patent rights in these inventions
have been assigned to the government of
the United States of America. The
prospective exclusive license territory
may be worldwide and the field of use
may be limited to the development,
manufacture and commercialization of
retrovirally-engineered mutated KRAS
TCR-based autologous peripheral blood
T cell therapy products as set forth in
the Licensed Patent Rights for the
treatment of human cancers.
DATES: Only written comments and/or
applications for a license which are
received by the National Cancer
Institute on or before September 1, 2016
will be considered.
ADDRESSES: Requests for copies of the
patent application, inquiries, and
comments relating to the contemplated
exclusive license should be directed to:
Andrew Burke, Ph.D., Licensing and
Patenting Manager, Technology Transfer
Center, National Cancer Institute, 9609
Medical Center Drive, MSC 9702,
Rockville, MD 20852; Telephone: (240)
276–5484; Email andy.burke@nih.gov.
SUPPLEMENTARY INFORMATION: The
present invention describes an isolated
T cell receptor (TCR) which recognizes
the G12D mutation of the Kristen rat
sarcoma viral oncogene homolog
(KRAS) protein within the context of
major histocompatibility complex HLA–
A11 presentation.
KRAS is an oncogene with a wellcharacterized role in the formation of
several human cancers, including:
Pancreatic, colorectal and lung. Certain
mutations, such as the substitution of
aspartic acid or valine for glycine at
codon 12 (termed G12D and G12V,
respectively), occur at relatively high
frequency and may represent amenable
targets for immunotherapies. Due to the
restricted expression of KRAS G12D in
pre-cancerous and malignant cells,
engineered T cell therapies based on the
present invention may be useful for the
treatment of select cancers.
PO 00000
Frm 00032
Fmt 4703
Sfmt 4703
54817
The prospective exclusive license will
be royalty bearing and will comply with
the terms and conditions of 35 U.S.C.
209 and 37 CFR part 404. The
prospective exclusive license may be
granted unless within fifteen (15) days
from the date of this published notice,
the NCI receives written evidence and
argument that establishes that the grant
of the license would not be consistent
with the requirements of 35 U.S.C. 209
and 37 CFR part 404.
Complete applications for a license in
an appropriate field of use that are
timely filed in response to this notice
will be treated as objections to the grant
of the contemplated exclusive license.
Comments and objections submitted to
this notice will not be made available
for public inspection and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
Dated: August 8, 2016.
Richard U. Rodriguez,
Associate Director, Technology Transfer
Center, National Cancer Institute.
[FR Doc. 2016–19549 Filed 8–16–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Aging; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Aging Initial Review Group; Neuroscience of
Aging Review Committee.
Date: September 29–30, 2016.
Time: 4:00 p.m. to 12:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: DoubleTree by Hilton Bethesda,
8120 Wisconsin Ave., Bethesda, MD 20814.
Contact Person: Jeannette L. Johnson,
Ph.D., Deputy Review Branch Chief, National
Institutes of Health, National Institute on
Aging, Gateway Building, Bethesda, MD
E:\FR\FM\17AUN1.SGM
17AUN1
Agencies
[Federal Register Volume 81, Number 159 (Wednesday, August 17, 2016)]
[Notices]
[Pages 54816-54817]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-19545]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood Institute; Notice of Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of a meeting of the
National Heart, Lung, and Blood Advisory Council.
The meeting will be open to the public as indicated below, with
attendance limited to space available. Individuals who plan to attend
and need special assistance, such as sign language interpretation or
other reasonable accommodations, should notify the Contact Person
listed below in advance of the meeting.
Name of Committee: National Heart, Lung, and Blood Advisory
Council.
Date: September 20, 2016.
Open: 1:00 p.m. to 5:00 p.m.
Agenda: To discuss program policies and issues.
Place: National Institutes of Health, Building 35A, Porter
Building, Room 640, 35A Convent Drive, Bethesda, MD 20892.
Contact Person: Valerie L. Prenger, Ph.D., MPH, Acting Division
Director, Division of Extramural Research Activities, National
Heart, Lung, and Blood Institute, 6701 Rockledge Drive, Room 7214,
Bethesda, MD 20892-7924, 301-435-0270, prengerv@nhlbi.nih.gov.
Any interested person may file written comments with the committee
by forwarding the statement to the Contact Person listed on this
notice. The statement should include the name, address, telephone
number and when applicable, the business or professional affiliation of
the interested person.
In the interest of security, NIH has instituted stringent
procedures for entrance onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles will be inspected
before being allowed on campus. Visitors will be asked to show one form
of identification (for example, a government-issued photo ID, driver's
license, or passport) and to state the purpose of their visit.
Information is also available on the Institute's/Center's home
page: www.nhlbi.nih.gov/meetings/nhlbac/index.htm, where an agenda and
any
[[Page 54817]]
additional information for the meeting will be posted when available.
(Catalogue of Federal Domestic Assistance Program Nos. 93.233,
National Center for Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839,
Blood Diseases and Resources Research, National Institutes of
Health, HHS)
Dated: August 11, 2016.
Michelle Trout,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2016-19545 Filed 8-16-16; 8:45 am]
BILLING CODE 4140-01-P